Variables | |
---|---|
Male/female | 35/40 |
Age, yrs | 52/46.75–62 |
Disease duration, yrs | 6.5/3–12 |
Articular manifestations (%) | |
Axial | 50.6 |
Peripheral arthritis | 91.9 |
Enthesitis | 41.4 |
Dactylitis | 22.6 |
Extraarticular manifestations (%) | |
Uveitis | 5.6 |
IBD | 1.3 |
DAS28-CRP* | 3.71/2.7–5.06 |
DAPSA | 20.6/13.6–29.6 |
Tender joint | 5/2–12 |
Swollen joint | 2/0–7 |
ESR, mm/h | 23/12.75–29 |
CRP, mg/dl | 0.8/0.39–1.2 |
PtGA | 52/40–65 |
VAS pain | 52.5/40–65 |
VAS physician | 45/35–50 |
HAQ | 0.75/0.62–1.25 |
PASI | 1.3/0–2.05 |
MASES | 1/0–2 |
Concomitant treatment at baseline (%) | |
DMARD | 49 (39.5) |
Prednisone intake | 39 (31.5) |
NSAID intake | 99 (79.8) |
Anti–TNF-α therapy (%) | |
ADA | 39 (31.4) |
ETA | 62 (50) |
GOL | 23 (18.5) |
PsA: psoriatic arthritis; TNF: tumor necrosis factor; IBD: inflammatory bowel disease; DAS28: 28-joint Disease Activity Score; DAPSA: Disease Activity Index for Psoriatic Arthritis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PtGA: patient’s global assessment; VAS: visual analog scale; HAQ: Health Assessment Questionnaire; PASI: Psoriasis Area and Severity Index; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs; ADA: adalimumab; ETA: etanercept; GOL: golimumab.